Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Novo Nordisk (NVO) and maintained a price target of $160.
March 20, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Novo Nordisk with a steady price target of $160.
The reiteration of an Overweight rating and the maintenance of a $160 price target by a reputable analyst like Louise Chen from Cantor Fitzgerald could instill confidence among investors and potentially lead to a positive short-term impact on Novo Nordisk's stock price. The analyst's endorsement serves as a strong signal of the stock's value and future prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100